title: Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs.
abstract: Total parenteral nutrition (TPN) is essential for patients with impaired gut function but leads to parenteral nutrition-associated liver disease (PNALD). TPN disrupts the normal enterohepatic circulation of bile acids, and we hypothesized that it would decrease intestinal expression of the newly described metabolic hormone fibroblast growth factor-19 (FGF19) and also glucagon-like peptides-1 and -2 (GLP-1 and GLP-2). We tested the effects of restoring bile acids by treating a neonatal piglet PNALD model with chenodeoxycholic acid (CDCA). Neonatal pigs received enteral feeding (EN), TPN, or TPN + CDCA for 14 days, and responses were assessed by serum markers, histology, and levels of key regulatory peptides. Cholestasis and steatosis were demonstrated in the TPN group relative to EN controls by elevated levels of serum total and direct bilirubin and also bile acids and liver triglyceride (TG) content. CDCA treatment improved direct bilirubin levels by almost fourfold compared with the TPN group and also normalized serum bile acids and liver TG. FGF19, GLP-1, and GLP-2 were decreased in plasma of the TPN group compared with the EN group but were all induced by CDCA treatment. Intestinal mucosal growth marked by weight and villus/crypt ratio was significantly reduced in the TPN group compared with the EN group, and CDCA treatment increased both parameters. These results suggest that decreased circulating FGF19 during TPN may contribute to PNALD. Moreover, we show that enteral CDCA not only resolves PNALD but acts as a potent intestinal trophic agent and secretagogue for GLP-2.
authors.affiliation: Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Baylor College of Medicine, Houston, Texas 77030, USA.
authors.forename: Ajay Kumar
authors.initials: AK
authors.lastname: Jain
authors.forename: Barbara
authors.initials: B
authors.lastname: Stoll
authors.forename: Douglas G
authors.initials: DG
authors.lastname: Burrin
authors.forename: Jens J
authors.initials: JJ
authors.lastname: Holst
authors.forename: David D
authors.initials: DD
authors.lastname: Moore
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001284:Atrophy; D002635:Chenodeoxycholic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D002779:Cholestasis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D004195:Disease Models, Animal; D005346:Fibroblast Growth Factors / Q000378:metabolism; D004763:Glucagon-Like Peptides / Q000378:metabolism; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D008107:Liver Diseases / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D010289:Parenteral Nutrition, Total / Q000009:adverse effects*; D013552:Swine; D016896:Treatment Outcome
chemical_list: D002635:Chenodeoxycholic Acid; D005346:Fibroblast Growth Factors; D004763:Glucagon-Like Peptides
references.citation: J Med Chem. 2008 Mar 27;51(6):1831-41
references.pmid: 18307294
references.citation: Gastroenterology. 2006 Feb;130(2 Suppl 1):S70-7
references.pmid: 16473076
references.citation: Am J Clin Nutr. 2000 Jun;71(6):1603-10
references.pmid: 10837305
references.citation: Mol Pharm. 2008 Jan-Feb;5(1):42-8
references.pmid: 18179175
references.citation: JPEN J Parenter Enteral Nutr. 1994 Jan-Feb;18(1):20-5
references.pmid: 8164298
references.citation: J Nutr. 2010 Dec;140(12):2193-200
references.pmid: 20980637
references.citation: Curr Opin Pediatr. 1997 Jun;9(3):270-5
references.pmid: 9229168
references.citation: Nat Clin Pract Gastroenterol Hepatol. 2007 May;4(5):277-87
references.pmid: 17476210
references.citation: Endocrinology. 2005 Jan;146(1):22-32
references.pmid: 15486229
references.citation: Exp Biol Med (Maywood). 2001 Jul;226(7):674-80
references.pmid: 11444103
references.citation: Semin Pediatr Surg. 2001 May;10(2):49-55
references.pmid: 11329605
references.citation: J Biol Chem. 2000 May 19;275(20):15482-9
references.pmid: 10809780
references.citation: Gastroenterology. 1995 Aug;109(2):355-65
references.pmid: 7615183
references.citation: Science. 1999 May 21;284(5418):1362-5
references.pmid: 10334992
references.citation: Diabetes. 2007 Oct;56(10):2501-10
references.pmid: 17664243
references.citation: Proc Soc Exp Biol Med. 1975 Sep;149(4):1000-4
references.pmid: 1166064
references.citation: Cell Metab. 2005 Oct;2(4):217-25
references.pmid: 16213224
references.citation: Br J Surg. 1983 Jul;70(7):398-400
references.pmid: 6871618
references.citation: J Pediatr. 1975 Feb;86(2):264-9
references.pmid: 803386
references.citation: Diabetes. 1994 Apr;43(4):535-9
references.pmid: 8138058
references.citation: Cell Metab. 2009 Sep;10(3):167-77
references.pmid: 19723493
references.citation: Endocrinology. 2004 Jun;145(6):2594-603
references.pmid: 14976145
references.citation: Dig Dis Sci. 2004 Oct;49(10):1664-71
references.pmid: 15573924
references.citation: J Clin Invest. 1984 Nov;74(5):1614-24
references.pmid: 6438153
references.citation: Cell Metab. 2011 Jun 8;13(6):729-38
references.pmid: 21641554
references.citation: J Lipid Res. 2009 Oct;50(10):1955-66
references.pmid: 19346330
references.citation: J Nutr. 2006 Oct;136(10):2547-52
references.pmid: 16988124
references.citation: Gastroenterology. 2007 May;132(6):2131-57
references.pmid: 17498508
references.citation: Endocrinology. 2002 May;143(5):1741-7
references.pmid: 11956156
references.citation: J Nutr. 2004 Jun;134(6):1467-74
references.pmid: 15173413